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Abstract
Indirect evidence for a microtubule-dependent vesicular hepatocellular transport of bile acids has accumulated. Since
inhibition of this transport by colchicine can be achieved only at high but not at low bile acid infusion rates we were
wondering whether this transport pathway shows a hepatic zonation or not. To answer this question we perfused isolated rat
livers antegradely or retrogradely, respectively, with unlabeled and labeled taurocholate or taurodeoxycholate. Inhibition of
microtubule-dependent bile acid transport was aimed at co-infusion of colchicine. Periportal cells eliminated the likewise
hydrophobic taurodeoxycholate as fast as the more hydrophilic taurocholate. In contrast, pericentral cells excreted
taurodeoxycholate much slower than taurocholate. Colchicine did not change the biliary taurocholate excretion profile in
periportal and pericentral cells. However, colchicine reduced significantly taurodeoxycholate excretion in pericentral but not
in periportal cells. It is concluded that a microtubule-dependent vesicular, colchicine-sensitive transport pathway seems to be
involved in the translocation of taurodeoxycholate in pericentral but not in periportal cells. Since such a vesicular bile acid
transport is regarded to be much slower than transcellular transport by diffusion, this observation may explain the much
slower excretion of hydrophobic bile acids like taurodeoxycholate in pericentral than in periportal cells under physiological
conditions. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Indirect evidence for a microtubule-dependent ve-
sicular hepatocellular translocation of bile acids has
accumulated [1]. Interestingly, in most studies biliary
bile acid excretion is inhibited by colchicine (an in-
hibitor of microtubule formation) only at high but
not at low bile acid perfusion rates [2]. To explain
this phenomenon it has been hypothesized that at
low perfusion rates bile acids might be translocated
only by cytosolic di¡usion and at high rates addi-
tionally by a microtubule-dependent mechanism.
Since hydrophobic bile acids like taurodeoxycholate
(TDC) are translocated much faster in periportal
than in pericentral cells [3] an alternative explanation
could be possible. If one assumes that the putative
microtubule-dependent pathway is predominantly
present in pericentral but not in periportal cells,
then bile acid translocation could only be inhibited
by colchicine when the sinusoidal bile acid load
reaches the pericentral zone, and this would be the
case only at high bile acid perfusion rates. In order
0167-4889 / 01 / $ ^ see front matter ß 2001 Elsevier Science B.V. All rights reserved.
PII: S 0 1 6 7 - 4 8 8 9 ( 0 1 ) 0 0 1 0 8 - 2
* Corresponding author. Fax: +49-761-270-2782;
E-mail : baumgart@ch11.ukl.uni-freiburg.de
BBAMCR 14762 13-6-01
Biochimica et Biophysica Acta 1539 (2001) 218^224
www.bba-direct.com
to test this hypothesis we perfused the isolated liver
antegradely and retrogradely with identical bile acid
rates and inhibited the putative microtubule-depen-
dent pathway by pretreatment with colchicine.
2. Materials and methods
Male Sprague^Dawley rats (300^400 g) were pur-
chased from Ivanovas (Kissleg, Germany). They
were maintained on a standard rat chow (Altromin,
Lage, Germany) and water ad libitum, and kept with
diurnal lighting. Rats were not starved prior to use.
Chemicals of highest purity were purchased from
Merck (Darmstadt, Germany) and Sigma (Munich,
Germany), polyethylene tubing (PE-50) for cannula-
tion of the bile duct from Clay Adams (Parsippany,
NJ, USA), and the venous cannulation set (Abbo-
cath-T 14 G) from Abboth (Sligo, Ireland). Unla-
beled taurocholate (TC) and TDC were bought
from Calbiochem (La Jolla, CA, USA). 14C-TC
and 14C-TDC were supplied by Amersham
(Braunschweig, Germany). For single pass perfusion
of the isolated liver a perfusion pump Multi¢x M 851
Magna (Schwinherr, Reutlingen, Germany) was
used.
Liver perfusion was performed as described earlier
[3]. Brie£y, isolated livers of male Sprague^Dawley
rats were perfused either in the antegrade direction
(in£ow: portal vein; out£ow: caval vein) to probe
intrinsic activity of periportal cells or in the retro-
grade direction (in£ow: caval vein; out£ow: portal
vein) to probe pericentral cells. After perfusion in
situ to remove blood constituents and insertion of
the biliary catheter (PE-50) the liver was excised
and transferred to the perfusion circuit. The liver
was perfused in single pass arrangement with oxy-
genated Krebs^Ringer bicarbonate solution contain-
ing 5 mM glucose for 30 min to recover from sur-
gery. Then, unlabeled bile acids (TC or TDC) were
added to the perfusate yielding a ¢nal perfusion rate
of 8 nmol/min/g liver. During co-infusion experi-
ments colchicine, a potent inhibitor of microtubule
formation, was added at the same time at a rate of 20
nmol/min/g liver [4]. It has been shown that this col-
chicine in£ow rate leads to complete saturation of its
hepatic binding sites [4]. Twenty minutes later a bo-
lus of the respective radiolabeled bile acid was in-
jected into the inlet cannula over 30 s (Fig. 1). Per-
fusate e¥uent was collected in 1 min intervals for the
¢rst 10 min; thereafter in 10 min intervals. Bile was
measured in 10 min intervals assuming a speci¢c
gravity of 1 mg/Wl. Labels in aliquots were counted
in a liquid scintillation spectrophotometer (1600-RT;
Fig. 1. Experimental design. After cannulation of the bile duct the rat liver was £ushed in situ with oxygenated Krebs^Ringer bicarbo-
nated bu¡er and freed from blood constituents. Then, the liver was excised and connected to the perfusion circuit. At time 0 isolated
liver perfusion was started with Ringer solution (4 ml/min/g liver). The liver was allowed to recover for 30 min from the operation
procedure before unlabeled bile acids were added to the perfusate. During co-infusion experiments colchicine was added at the same
time as the unlabeled bile acids, and both substrates were infused at a constant rate until the end of the perfusion period (110 min).
Twenty minutes later a labeled tracer bolus of the respective bile acid was injected over 30 s. Perfusate e¥uent and bile were collected
at 1 and 10 min intervals, respectively, to determine label net uptake and label in bile.
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Packard, Frankfurt, Germany) to determine bile acid
uptake and biliary excretion pro¢le. In a separate set
of experiments colchicine was replaced by its stereo-
isomer lumicolchicine which has no inhibitory e¡ect
on microtubules.
3. Calculations and statistics
Uptake was calculated from the di¡erence between
label injected and label in the perfusate e¥uent.
Most label appeared in the perfusate e¥uent within
the ¢rst minute after bolus injection; no label was
detectable anymore beyond the third minute after
bolus injection in the outlet perfusate. Therefore, la-
bel in the perfusate e¥uent within the ¢rst 3 min
after bolus injection was considered as never having
been taken up by the liver [5]. Four to ¢ve experi-
ments were performed per study group. Di¡erences
between two sets of data were analyzed by the two-
tailed Student’s t test; di¡erences between several
sets by one-way analysis of variance (ANOVA). P
values of 9 0.05 were considered statistically signi¢-
cant. 4. Results
First pass extraction of bile acids by the liver was
s 90% in all perfusions, regardless of the perfusion
direction and bile acid species. This was true for
perfusions with the bile acids alone as well as for
co-perfusions of bile acids with colchicine.
Fig. 2 depicts the cumulative biliary recovery of
label during antegrade perfusion of the liver with
TC alone and TC combined with colchicine, respec-
tively. Over 90% of the label net uptake could be
found in bile within the ¢rst 10 min after bolus in-
jection. Thirty minutes after label injection virtually
all label had been excreted in bile. There was no
di¡erence of the biliary excretion kinetics between
perfusions with and without colchicine (Ps 0.05).
Fig. 3 demonstrates the cumulative biliary secre-
tion pro¢le of label during retrograde perfusion of
the liver with TC alone or TC and colchicine, respec-
tively. Excretion was slower as compared to ante-
grade perfusion which is in line with previous work
[6,7], but again, no di¡erence could be observed be-
tween perfusions with single TC and TC plus colchi-
cine (Ps 0.05). In both settings, recovery of label 30
min after its injection was almost complete.
Fig. 2. Cumulative biliary recovery of label during antegrade
perfusion of the liver with TC alone and TC combined with
colchicine. There was no di¡erence in biliary excretion kinetics
between perfusions with and without colchicine (Ps 0.05). TC,
taurocholate.
Fig. 3. Cumulative biliary secretion pro¢le of label during retro-
grade perfusion of the liver with TC alone or TC and colchi-
cine. No di¡erence could be observed between perfusions with
single TC and TC plus colchicine (Ps 0.05). TC, taurocholate.
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Fig. 4 illustrates the cumulative biliary secretion of
labeled TDC with and without co-infusion of colchi-
cine during antegrade perfusion. The kinetics equal
those of TC (see Fig. 2) and, again, were not di¡er-
ent between single bile acid and combined perfusions
(Ps 0.05). The TDC excretion pro¢le during ante-
grade perfusion is identical to that obtained in pre-
vious work [3].
Fig. 5 delineates the pattern of cumulative biliary
secretion of labeled TDC with and without colchicine
during perfusion in the retrograde direction. During
perfusion with single TDC radioactivity was fully
recovered in bile 60 min after its injection. TDC ex-
cretion during backward perfusion is retarded as
compared to antegrade perfusion (see Fig. 4) which
con¢rms earlier work [3,5]. In the presence of colchi-
cine during retrograde perfusion 14C-TDC was se-
creted into bile to a much lesser degree than without
colchicine pretreatment. This was already signi¢cant
at the ¢rst collection interval at 10 min (P6 0.05)
and kept on until the end of the perfusion run
(P6 0.01). Excretion of label virtually ceased 30
min after its application.
Fig. 6 compares the cumulative biliary secretion
characteristics of 14C-TDC in the presence of colchi-
cine and lumicolchicine (a stereoisomer of colchicine
without inhibitory e¡ects on microtubules), respec-
tively, during retrograde perfusion. Lumicolchicine
Fig. 4. Cumulative biliary secretion of labeled TDC with and
without co-infusion of colchicine during antegrade perfusion.
The kinetics equal those of TC (see Fig. 2) and, again, were
not di¡erent between single bile acid and combined perfusions
(Ps 0.05). TC, taurocholate; TDC, taurodeoxycholate.
Fig. 5. Cumulative biliary secretion of labeled TDC with and
without colchicine during perfusion in the retrograde direction.
In the presence of colchicine during retrograde perfusion 14C-
TDC was secreted into bile to a much lesser degree than with-
out colchicine pretreatment. This was already signi¢cant at the
¢rst collection interval at 10 min (P6 0.05) and kept on until
the end of the perfusion run (P6 0.01). Excretion of label vir-
tually ceased 30 min after its application.
Fig. 6. Cumulative biliary secretion characteristics of 14C-TDC
in the presence of colchicine and lumicolchicine (a stereoisomer
of colchicine without inhibitory e¡ects on microtubules) during
retrograde perfusion. Lumicolchicine did not a¡ect biliary secre-
tion of labeled TDC (compare Fig. 5) (Ps 0.05). Thus, inhibi-
tion of TDC secretion in pericentral cells by colchicine was spe-
ci¢c. TDC, taurodeoxycholate.
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did not a¡ect biliary secretion of labeled TDC; ki-
netics were identical to those of retrograde TDC per-
fusions (see Fig. 5) (Ps 0.05). Thus, inhibition of
TDC secretion in pericentral cells by colchicine was
speci¢c.
5. Discussion
To probe the functional liver heterogeneity with
respect to di¡erent intrinsic properties in periportal
and pericentral cells by means of antegrade and ret-
rograde perfusion of the liver a portal-central con-
centration gradient for the test compound must exist.
This has been shown for TC and TDC [3,5,6]. In this
study we used a bile acid in£ow rate of 8 nmoles/
min/g liver. This is several times less than we used in
earlier studies observing still a steep bile acid concen-
tration gradient since uptake was greater than 90%
[3,5,7]. Using this comparatively low bile acid in£ow
rate of 8 nmoles/min/g liver an even steeper bile acid
concentration gradient may be expected. Finally, the
di¡erent results in regard to biliary excretion kinetics
during antegrade and retrograde perfusions prove
involvement of hepatocytes from di¡erent zones dur-
ing perfusion in either direction. For these reasons it
is reasonable to assume that we have measured pre-
dominantly periportal hepatocyte function during
antegrade and pericentral hepatocyte function during
retrograde perfusion.
The di¡erent bile acid excretion patterns in peri-
portal and pericentral cells during perfusions without
colchicine are in line with earlier studies [3,5^7]. The
result that the hydrophilic TC is more rapidly trans-
located through the pericentral cells than the likewise
hydrophobic TDC is a con¢rmation of one of our
recent works [8].
As tested in separate perfusions colchicine and lu-
micolchicine did not alter basal bile £ow (data not
shown) which is in line with studies performed by
others [2,4,9,10]. However, colchicine has been
shown to be a very e¡ective compound to disrupt
microtubule-dependent processes [1,2,4,9,11,12]. All
these studies have in common that they investigated
the impact of colchicine with respect to the whole
liver. It is very interesting that studies dealing with
inhibition of bile acid secretion by colchicine report
an e¡ect of this inhibitor only at high infusion rates
but not when low infusion rates were used. From
those studies it was concluded that a microtubule-
dependent, colchicine-sensitive mechanism of biliary
bile acid secretion is recruited when the liver is sub-
jected to high bile acid loads. This conclusion may be
true, but considering the substrate concentration gra-
dient within the liver acinus an alternative, or addi-
tional, explanation is possible: with increasing rates
of bile acids infused, the portal-central bile acid con-
centration gradient stretches and ¢nally spills over to
the pericentral area. Provided that in the pericentral
area the microtubule-dependent pathway is more de-
veloped than in the periportal area, one could under-
stand why transcellular bile acid translocation is
more e¡ectively inhibited by colchicine when infusing
higher bile acid rates. Additionally, the pericentral
area could be more susceptible to colchicine treat-
ment than the periportal one. Using 8 nmoles/min/g
liver in our study we can assume that the bile acid
concentration gradient is limited to the zone of entry.
The bile acid infusion rates used by Crawford et al.
[11] are about 10 times higher preceded by a large i.v.
bolus injection. Therefore, it is very likely that in
their studies the pericentral area was involved in
bile acid translocation. No matter how, our results
clearly demonstrate a greater susceptibility of the
pericentral than the periportal cells to colchicine
treatment with respect to the translocation of the
hydrophobic TDC.
Adding our results to the data obtained by others
[2,11] one may hypothesize that bile acid transloca-
tion in periportal cells does not require a microtu-
bule-dependent (vesicular) pathway, at least not at
the bile acid in£ow rates used in this study. This is
supported by data which we have gathered when
perfusing the isolated liver antegradely with bile salts
di¡ering in their physico-chemical properties. There
were no signi¢cant di¡erences in bile acid transloca-
tion times, irrespective of the hydrophilicity of the
infused bile acid [8]; in contrast, pericentral cells
translocate bile acids the slower the more hydropho-
bic they are [8]. If one postulates further that in
pericentral cells (in contrast to periportal cells) bile
acids are translocated increasingly by a microtubule-
dependent process the more hydrophobic they are,
then one could ¢nally explain why, under physiolog-
ical conditions, the di¡erence in bile acid transloca-
tion time between periportal and pericentral cells is
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the greater the more hydrophobic the bile acids are
[3,7,8].
An array of studies with respect to sinusoidal up-
take, transcellular transport and canalicular excre-
tion of bile acid is now available [13^20]. Most of
these studies do not refer to the heterogeneity of the
liver parenchyma. Groothuis et al. [6] were the ¢rst
to demonstrate autoradiographically a declining cen-
tral-portal bile acid concentration gradient during
retrograde perfusion of the isolated perfused liver
and a di¡erent biliary bile acid excretion pattern in
periportal and pericentral cells. We demonstrated for
the ¢rst time di¡erences in bile acid processing in
periportal and pericentral cells [3] which changes in
response to environmental alteration [5,21^23]. Since
then, many others have extended the knowledge
about zonal bile acid processing, mainly by selective
destruction of either the portal or the central zone of
the liver acinus [24^27]. Finally, over the last 20
years many studies pointed to an important role of
intracellular vesicles derived from intracellular or-
ganelles, mostly from the Golgi apparatus and the
endoplasmic reticulum [1]. Although enrichment of
pericanalicular vesicles and an increase in the
amount of Golgi-rich area and Golgi membranes
could be demonstrated after bile acid load by elec-
tron microscopy and autoradiography [28^31], little
attention was paid to the zonal distribution of these
¢gures. The same holds true for studies with immu-
noperoxidase and immuno£uorescence [32]. A reason
for this might be the di⁄cult histological analysis of
the complex three-dimensional architecture of the liv-
er acinus. Nevertheless, to clarify further the role of a
putative microtubule-dependent vesicular bile acid
transport the studies just mentioned above should
be repeated or reevaluated, respectively, with special
view to the acinar distribution including not only
antegrade but also retrograde liver perfusion.
In summary, we have demonstrated a hepatic zo-
nation of colchicine-sensitive TDC transport. Colchi-
cine reduces signi¢cantly biliary excretion of TDC in
pericentral but not in periportal cells. The results are
best explained by assuming that pericentral cells, in
contrast to periportal cells, translocate hydrophobic
bile acids like TDC at least in part via a microtubule-
dependent vesicular pathway. This assumption would
also explain why pericentral cells translocate hydro-
phobic bile acid much slower than periportal cells
since bile acid translocation by vesicular transport
is regarded much slower than that by di¡usion.
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